The proteasome inhibitor carfilzomib (Cfz) induces cardiotoxicity in vivo: molecular mechanisms and the cardioprotective effect of metformin (Met)

Georgios Kremastiotis; Panagiotis Efentakis; Aimilia Varela; Constantinos H. Davos; Maria Tsoumani; Eleni‐Dimitra Papanagnou; Ioannis P. Trougakos; Efstathios Kastritis; Zoi Kanaki; Efstathios K. Iliodromitis; Apostolos Klinakis; Meletios A Dimopoulos; Evangelos Terpos; Ioanna Andreadou

doi:10.1016/j.yjmcc.2018.05.102

Related publications

Article2018

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin

Panagiotis Efentakis, Georgios Kremastiotis, Aimilia Varela, Panagiota Nikolaou, Eleni‐Dimitra Papanagnou, Constantinos H. Davos, Maria Tsoumani, Georgios Agrogiannis, Anastasia Konstantinidou, Efstathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioannis P. Trougakos, Ioanna Andreadou, Evangelos Terpos

Article2017

Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Eleni‐Dimitra Papanagnou, Ioannis P. Trougakos, Eftathios Kastritis, Evangelia Chavdoula, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos

Article2018

P4787Investigating the molecular mechanisms of carfilzomib-induced cardiotoxicity and the emerging role of metformin as a prophylactic therapy

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Eleni‐Dimitra Papanagnou, Ioannis P. Trougakos, Efstathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Evangelos Terpos, Ioanna Andreadou

Article2018

Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Maria Tsoumani, Georgios Agrogiannis, Anastasia Konstantinidou, Eleni‐Dimitra Papanagnou, Ioannis P. Trougakos, Eftathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos

Article2022

Elucidating the cardiac outcomes of irreversible proteasome inhibitor Carfilzomib in in vivo models of HFpEF and HFrEF. Preventive role of Metformin

Panagiotis Efentakis, Sofia Lamprou, Aimilia Varela, Papanagnou Eleni-Dimitra, Andriana Christodoulou, Maria Gavriatopoulou, Constantinos H. Davos, Ioannis Trougkakos, Meletios A Dimopoulos, Evangelos Terpos, Ioanna Andreadou

The proteasome inhibitor carfilzomib (Cfz) induces cardiotoxicity in vivo: molecular mechanisms and the cardioprotective effect of metformin (Met)

Discussion(0)

Related publications

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin

Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms

P4787Investigating the molecular mechanisms of carfilzomib-induced cardiotoxicity and the emerging role of metformin as a prophylactic therapy

Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo

Elucidating the cardiac outcomes of irreversible proteasome inhibitor Carfilzomib in in vivo models of HFpEF and HFrEF. Preventive role of Metformin